Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

This is a randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma


To evaluate, in a randomised phase 2 study, the efficacy of paclitaxel with or without the MEK inhibitor GSK1120212 (of which the most tolerable dose has been confirmed) or pazopanib in wild type BRAF metastatic melanoma, stratifying for NRAS mutation status.




  • Progression free survival


  • Objective response rate.
  • Progression free survival at 6 months
  • Safety of the GSK1120212/paclitaxel and pazopanib/paclitaxel combination
  • Overall survival.


The primary results publication can be found here.